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Background: The selective occurrence of hepatotoxicity observed with use of pazopanib may be attributed to its
high level of plasma protein binding and low hepatic extraction ratio. The primary objective was to investigate
changes in free drug concentration amongst patients with varying albumin concentrations.
Methods: A HPLC-MS/MS method using C18 column (4.6  150 mm, 5 μm) with ESI source in positive mode had
been developed and validated for the quantitative determination of free pazaopanib concentration in human
plasma. Prior to sample preparation, patient samples were subjected to 6-hour equilibrium dialysis with molecular
weight cut-off set at 8000 Da.
Results: The calibration curves were linear over the range of 5–1000 ng/mL, with a lower limit of quantification of
5 ng/mL. The intra-day and inter-day precisions and accuracies were all within  15 %, at 3 different quality
controls. Higher median fraction unbound of pazopanib were observed in patients (n ¼ 17) with lower than
normal albumin concentrations.
Conclusion: With the developed assay, monitoring of plasma free concentrations may be evaluated as an indicator
of pazopanib exposure in patients.1. Introduction
Pazopanib (Votrient ®) is a drug indicated for the treatment of
advanced renal cell carcinoma. It belongs to the drug class of tyrosine-
kinase inhibitors that targets vascular endothelial growth factor re-
ceptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet derived growth factor
receptor and stem cell growth factor receptor (c-Kit) [1]. The current
dosing guidelines recommend a starting dosage of 800 mg once daily for
treatment [2]. In particular, there have been concerns of hepatotoxicity
with the use of pazopanib [3, 4, 5, 6] because a high proportion of renal
cancer patients (up to 40–50%) had experienced increases in serum
transaminases and bilirubin in clinical trials, leading to a black box
warning mandated by US Food and Drug Administration (FDA) in 2012
[7].
To investigate the effect of pazopanib-induced hepatotoxicity, a
quantification method for plasma free drug concentration of pazopaniborm 10 February 2020; Accepted
vier Ltd. This is an open access arwill be useful to correlate with drug exposure. Since free drug molecules
traverse cell membranes and diffuse more efficiently to exert therapeutic
effects, plasma free drug concentration may be a more appropriate in-
dicator of the related toxicological response. This is especially pertinent
for drugs such as pazopanib that are highly bound to plasma proteins
because free drug concentrations may fluctuate even without obvious
change to total drug concentration. Therefore, free drug quantification is
more likely to correlate better with target tissue exposure and toxicity
than total drug concentration [8].
To date, most other studies had correlated drug exposures with
measures that depend on total drug concentrations such as trough con-
centrations (Cmin) and Area under the curve (AUC), mainly due to its
convenience of sampling and ease of preparation [9, 10, 11, 12]. While a
quantitative method for free drug concentration of pazopanib with a
lower limit of quantification at 0.5 mcg/mL had been developed by
Escudero et al, the reported use of a UV detector may face challenges of16 April 2020
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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unique mass transitions to identify compounds would be more reliable as
compared to the use of retention times because compounds of similar
chemical structures may co-elute together. Hence, the primary aim of our
study was to develop a sensitive analytical method using high perfor-
mance liquid chromatography-tandem mass spectrometry
(HPLC-MS/MS) coupled with equilibrium dialysis to quantify plasma free
drug concentration of pazopanib, for use in patient samples.
The unique pharmacokinetic profile of pazopanib presents additional
challenge for the management of its related hepatotoxicity problem.
Pazopanib exhibits very high level of plasma protein binding (>99.9%),
mainly bound to albumin [8]. Although pazopanib is extensively
metabolized in the liver by CYP3A4 enzymes, it exhibits a low calculated
hepatic extraction ratio of 0.00346 (<0.3). The implication lies in that
clearance of pazopanib is independent from blood flow and depends
mainly on intrinsic clearance and plasma protein binding [2]. Mathe-
matically, this increases the risk that a small change in the percentage of
plasma protein binding would lead to a disproportionate change in
plasma free drug concentration. In the clinical context, inter-patient
variability in the level of plasma proteins is likely to accentuate the
variation in free drug concentration [14, 15, 16].
For this reason, we also hypothesized that a lower albumin level will
implicate a higher fraction unbound (fu%). This could be explained by
the fact that this patient group will be having fewer plasma proteins
made available for binding to drugs. Also, hypoalbuminemia underscores
poor liver function which could lead to decrease in intrinsic clearance
and potentially, an elevation of free drug concentration. Thus, our sec-
ondary goal was to apply our developed method to investigate the rela-
tionship between albumin levels and plasma free drug concentrations of
pazopanib using equilibrium dialysis as a non-disruptive approach to
preserve its intrinsic binding affinity. Using actual patient plasma sam-
ples, we then seeked to evaluate the correlation between the two afore-
mentioned variables of interest for clinical application.
2. Materials and methods
2.1. Chemicals and reagents
Pazopanib was purchased from LC Laboratories ® (Woburn, MA,
USA) while erlotinib (internal standard, IS) was obtained from BioVision
® (South Milpitas, CA, USA). Acetonitrile (ACN) [High performance
liquid chromatography (HPLC) grade] was obtained from Tedia ®
(Fairfield, OH, USA) while formic acid (reagent grade) was from Sigma-
Aldrich (St Louis, MO, USA). Pooled human plasma was obtained from
Biowest ® (Kansas City, MO, USA) and 10  Phosphate buffered saline
(PBS) of ultra-pure grade was purchased from Vivantis ® (Selangor,
Malaysia). Rapid Equilibrium Dialysis (RED) devices with a molecular
weight cut-off of 8000 Da were purchased from Thermo Fisher Scientific
(Rockford, IL, USA).2.2. Instruments and conditions
The LC-MS/MS setup consisted of high-performance liquid chroma-
tography (HPLC) system (Agilent Technologies HPLC 1200 Series, Cali-
fornia, USA) coupled to a triple quadruple mass spectrometer (QTRAP ®
3200, AB SCIEX, Framingham,MA, USA). Chromatographic separation of
pazopanib and IS were carried out using an Agilent C18 Column (4.6 Table 1. Analyte specific parameters of pazopanib and erlotinib (Internal Standard).
ANALYTE ANALYTE SPECIFIC PARAMETERS
Parent mass (m/z) Product mass (m/z) Collision energy (V) Declusterin
PAZOPANIB 438.3 357.2 39 53
ERLOTINIB (IS) 394.5 278.1 41 42
2150 mm, 5 μm, Santa Clara, California, USA). The injection volume used
was 10 μL and total chromatographic run time was 10.0 min. The mobile
phase used consisted of 0.1% v/v formic acid in water (A) and 0.1% (v/v)
formic acid in ACN (B). At a flow rate of 1 mL/min, the gradient condi-
tions were set as follows: 80A:20B from 0-3 min, 50A:50B from 3-7 min
and 80A:20B from 8-10 min.
Quantification was subsequently carried out via positive electrospray
ionization (ESI) multiple reaction monitoring (MRM). The chosen pre-
cursor to product ions (Q1/Q3) selected for pazopanib and erlotinib were
set at the m/z (mass: charge ratio) of 438.3/357.2 and 394.5/278.1
respectively. For mass spectrometer parameters, ion spray voltage was
5000 V and temperature was 550 C. Curtain gas, nebulizer gas and the
heater gas were ultrahigh purity (UHP) nitrogen gas and their pressures
were adjusted to 25, 50 and 55 psi respectively (Table 1). Following the
LC-MS/MS run, the acquired data was processed with Analyst® software
version 1.4.2 (AB SCIEX, Framingham, MA, USA).
2.3. Preparation of stock solutions, calibration standards and quality
controls
Stock solutions containing pazopanib (5.0 mg/mL) and erlotinib (2.5
mg/mL) were prepared in dimethyl sulfoxide (DMSO) and stored at -20
C. Working solutions were diluted down from stock solutions using
ACN: H2O (1:1) using serial dilution. A set of eight non-zero calibration
standards (5, 10, 25, 50, 100, 250, 500, 1000 ng/mL) were prepared by
adding the appropriate pazopanib working solutions into pooled human
plasma. QC samples of 12 ng/mL (QC low), 120 ng/mL (QC medium),
900 ng/mL (QC high) and Lower Limit of Quantification (LLOQ) sample
of 5 ng/mL were prepared in the same manner and in triplicates.
2.4. Pre-treatment of calibration standards and quality controls
Firstly, 95 μL of pooled human plasma was pipetted to a 2 mL
Eppendorf tube, followed by 5 μL of the respective pazopanib working
solution (concentrations described in Section 2.3), 100 μL of PBS and 20
μL of internal standard (500 ng/mL). 1.4 mL of diethyl ether was added
for liquid-liquid extraction, using positive-displacement pipettes (Gilson,
Middleton, USA). The tube was vortex-mixed for 3 min, followed by
centrifugation at 10,000 rpm for 10 min. The upper layer was then
extracted into a 1.5 mL tube and evaporated to dryness under a stream of
nitrogen gas at 37 C. The samples were then reconstituted in 200 μL of
the mobile phase consisting of equal volumes of 0.1% v/v formic acid in
water (A) and 0.1% v/v formic acid in ACN (B) for the chromatographic
runs.
2.5. Preparation of patient plasma samples
With written informed consent, 17 patient samples were recruited
from the National Cancer Centre, Singapore (NCCS) between January
2014 to January 2016. The inclusion criteria extend to patients who were
already receiving standardized oral pazopanib 800 mg daily for the past
week. Patients whowere receiving treatment that involves a combination
of tyrosine kinase inhibitors were excluded. The blood sample was then
centrifuged at 3000 rpm to separate the plasma from the buffy coat. 1 mL
of plasma was collected and stored in cryotubes at -20 C until analysis.
This study had been approved by the SingHealth Institutional Review
Board (IRB) approval (CIRB Ref 2012/077/F).g potential (V) Entrance potential (V) Exit potential (V) Typical retention time (min)
6 4 5.00
4 3 5.30
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and free drug concentration using the following method: Single-Use Plate
Rapid Equilibrium Dialysis (RED) Device (Thermo Fisher Scientific,
Rockford, USA) with a molecular weight cut-off of 8000 Da was used. A
total of 300 μL of the patient plasma and 500 μL of Phosphate Buffered
Saline (PBS) were loaded into the sample chamber and buffer chamber
respectively, according to manufacturer's instructions. The samples were
then incubated at 37 C on an orbital shaker (LM-570D, Yihder Tech-
nology, Xinbei, China) at 250 rpm for 6 h to establish equilibrium.
Content from both sample and buffer chambers was collected after
equilibrium dialysis. Liquid-liquid extraction was performed on the
sample using diethyl ether where the upper layer was then collected and
evaporated to dryness under a stream of nitrogen gas. The samples were
then reconstituted in the 200 μL of mobile phase consisting of equal
volumes of 0.1% v/v formic acid in water (A) and 0.1% v/v formic acid in
ACN (B). This was done in technical duplicates for each patient sample.
The fraction unbound (fu%) was determined using the following
equation: fu% ¼ (concentration of analyte in buffer chamber/concen-
tration of analyte in plasma chamber)  100%2.6. Data analysis
Each sample used for calibration standards (concentrations described
in Section 2.3) was quantified in triplicates and the mean peak area ratio
of pazopanib: IS was quantified against pazopanib: IS concentration (ng/
mL) to determine the reliability of the LC-MS/MS method. The least-
squares linear regression analysis was employed to plot the calibration
curves, using a weighting factor of 1/x2. The validation of the method
was carried out following guidelines for Bioanalytical Method Validation
published by the FDA for precision, accuracy, selectivity, sensitivity,
carry-over effect, recovery and stability [7]. Statistical analysis was
conducted using Statistical Package for the Social Sciences (SPSS, IBM),
and p-values less than 0.05 were considered statistically significant.
3. Results and discussion
3.1. Linearity and limit of quantification
The linearity of calibration curves for pazopanib expressed as correla-
tion coefficients (R2) was at least 0.99. The average least square linear
regression parameters were as follows: y ¼ 0.2200 x (0.018) þ 0.0560
(0.0192). The final calibration curves ranged from 5-1000 ng/mL. The
upper limitwas imposedbecause itwas found that athigher concentrations,
there might be ion suppression effect in which simultaneous processing of
more than one component in the ion source could result in competition and
reduction in mass spectrometry signal, leading to a plateau.Table 2. Intra-day and inter-day precision and accuracy expressed as percentages (%
analytical runs.
Nominal concentration (ng/mL) Intra-day precision (%) Intra-day
LLOQ (5 ppba) 8.23 97.06
12.13 119.89
15.58 111.98
QC Low (12 ppb) 1.67 91.80
1.10 102.06
11.62 96.98
QC Medium (120 ppb) 1.16 109.33
12.31 101.71
4.44 98.38
QC High (900 ppb) 1.60 109.56
1.73 96.52
12.24 88.83
a units for Quality Controls measured in parts per billion.
33.2. Validation
3.2.1. Precision and accuracy
Precision was calculated using the formula: (standard deviation of
measured concentration/mean measured concentration)  100%; while
accuracy was determined using the formula of (measured concentration/
nominal concentration)  100%.
To investigate intra-day precision and accuracy, three replicates of
eachQC samples (QC low,medium and high)were prepared and analysed
in one analytical run. To investigate inter-day precision and accuracy, a
total of three analytical runs were performed on three separate days.
For plasma samples, intra-day precision ranged from 1.16-12.31%
and inter-day precision ranged from 5.29-10.80%. Intra-day and inter-
day accuracies of QC samples ranged from 91.80-109.56% and
95.22–103.14% respectively. For LLOQ, the intra-day and inter-day
precisions were 8.23–15.58% and 10.57% while the intra-day and
inter-day accuracies were 97.06–111.98% and 109.64% accordingly
(Table 2). Overall, these values were within the allowance set by FDA of
15% for QC samples and within 20% for LLOQ samples.
3.2.2. Selectivity, sensitivity and carry-over
Our method is selective since the chromatograms showed clear sep-
aration between analyte and IS with little interference. Our method is
also sensitive as the signal at the LLOQ was found to be at least five times
of the blank sample. Figure 1A depicted a representative chromatogram
for a blank response. There was no significant carry-over effect found,
with minimal difference in the readings of blanks before and after a run
of QC high (900 ng/mL). Figure 1B and C depicted a representative
chromatogram of a calibration standard and patient plasma sample
spiked with internal standard respectively.
3.2.3. Recovery
For the preparation of neat samples, 195 μL of mobile phase, 5 μL of
pazopanib working solution and 20 μL of internal standard (500 ng/mL)
were pipetted into an Eppendorf tube. The extraction recovery was
calculated with the following formula: recovery ¼ (mean peak area of
drug extracted from plasma/mean peak area of non-extracted neat
samples)  100%. At concentration 12, 120 and 900 ng/mL, the mean
recoveries were found to be 123.67%, 113.48%, 114.56% respectively.
3.2.4. Stability
Stability tests of pazopanib were done using the QC samples (low,
medium and high) as summarised in (Table 3). No significant degrada-
tion of the QC samples of pazopanib was detected after storing the
samples at bench top conditions, auto sampler conditions or after 1
month of storage at -80 C. Three freeze-thaw cycles also did not result in) from nominal controls obtained from Quality Control (QC) samples in three
accuracy (%) Inter-day precision (%) Inter-day accuracy (%)
10.57 109.64
5.29 95.22
5.44 103.14
10.80 98.30
Figure 1. Chromotograms of pazopanib and internal standard for blank
response (A), calibration standard (B) and actual patient plasma sample spiked
with internal standard (C). Blue color denotes pazopanib (m/z of 438.3/357.2)
while red line denotes internal standard of erlotinib (394.5/278.1).
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various stability tests were found to be within the acceptable allowance
of 15% [7].3.3. Equilibrium dialysis of actual patient samples
A total of 17 patients' plasma samples were tested with our developed
method. Their mean serum albumin level was 38.3  6.3 g/L, with 3 of
the patients presented with hypoalbuminemia (defined as when albumin
concentration falls below 35 g/L). The optimal time to reach equilibrium
dialysis was chosen to be 6 h according to a previously validated method
[15]. The average steady state concentration of our measured patients'
samples was 30.9  11.2 μg/mL, consistent with what had been reported
in studies [2, 16] while free drug concentration of pazopanib in our4measured patients’ samples was found to be 5.84  3.02 ng/mL
(expressed in mean  standard deviations). There were no statistically
significant differences between free drug concentration of pazopanib in
our range of plasma albumin levels of 29–44 g/L.
3.4. Effect of variable albumin levels in human plasma on fu% of
pazopanib
Patients' plasma samples were subsequently categorized into 3 groups
of varying levels of albumin, with very low albumin level and low al-
bumin level being defined as less than 30 g/L and less than 40 g/L
respectively (Table 4). The median fraction unbound was observed to be
higher in patients’ samples with lower than normal albumin levels
(0.0173  0.0060 and 0.0227  0.0122 in very low and low albumin
levels respectively) compared to patients with normal albumin level
(0.0129  0.0061). Comparing plasma free drug concentrations, higher
median plasma free drug concentration was trended for patient group
with low albumin level when compared to patient samples with very low
and normal levels (6.49  3.65 ng/mL vs 3.44  1.32 ng/mL and 4.88 
2.71 ng/mL). It was noteworthy that the limited number of patients
belonging to very low albumin levels (n ¼ 2) may have made it difficult
to draw robust inferences for basis of comparison. The effect of varying
albumin levels on fu% of pazopanib in actual patient plasma samples
would need to be further demonstrated using a patient cohort of larger
sample size with wider albumin range for it to be meaningful.
When interpreting this data to understand the reason behind toxicity,
fu% serves as a surrogate measure for the changes to free drug concen-
tration of pazopanib. In patients with severe hypoalbuminemia, we
would be concerned if the total pazopanib concentration may be mis-
interpreted as a falsely lower exposure to free active pazopanib than what
was reflected in the patient. Thus, our findings had provided greater
depth to interpret free drug concentration of pazopanib in the event of
therapeutic drug monitoring [17, 18, 19, 20] and could allow physio-
logically based pharmacokinetic models to be built. There could be po-
tential use of albumin levels to complement laboratory liver function
tests to guide clinicians in dosage adjustments such as using lower doses
to minimise drug-use related adverse events. Given how pazopanib is
currently used with a standard fixed dose despite it showing wide
inter-patient variability in terms of treatment outcome, the measure of
free drug concentration in relation to albumin levels could be adopted to
refine clinical practice in the future. The use of serum albumin levels is
currently being employed in clinical practice for anti-epileptic drugs such
as phenytoin, in which albumin level is considered as a correction factor
to measure for free phenytoin [21].
There are a few method limitations worth mentioning: our method
had been validated based on total drug concentration of pazopanib
spiked in pooled human plasma because quantitative determination of
plasma free drug concentration in the buffer compartment had been
challenging, given how their absolute values were near the LLOQ range.
Also, the accuracy of the measured buffer concentration would be
especially prone to influence of non-specific binding and/or change in
volume [22]. The use of RED device also relied on the assumption that
equilibrium had been achieved within the predetermined incubation
time and limits assay usage in setting that requires fast turnovers.
While several methods had been documented in literature for
simultaneous quantification of tyrosine-kinase inhibitors [23, 24, 25],
related drugs of interest [26] and/or its metabolites [27, 28], our study
had allowed for the additional determination of unbound drug concen-
tration. Before clinical application, our findings still need to be further
validated in a larger independent patient cohort and consider
patient-related factors such as the concurrent medications and the pres-
ence of underlying comorbidities. Future work could utilise the approach
for quantification of drugs with narrow therapeutic window that has a
similar pharmacokinetic profile of highly protein-bound and low hepatic
extraction ratio.
Table 3. Stability data of pazopanib at various conditions expressed as precision and accuracy in percentages from nominal concentration.
Stability Test Conditions Concentrations Precision (%) Accuracy (%)
Autosampler Extracted samples stored for 14 h at room temperature 12 ppba 10.43 96.45
120 ppb 5.78 96.56
900 ppb 5.28 96.02
Freeze Thaw Three freeze thaw cycles 12 ppb 1.40 93.79
120 ppb 12.39 93.50
900 ppb 3.51 100.49
Bench Top Plasma samples stored at room temperature for 8h 12 ppb 4.10 113.11
120 ppb 7.80 93.21
900 ppb 7.31 97.02
Long Term Stored at -80 C for 1 month 12 ppb 4.35 100.58
120 ppb 4.36 113.89
900 ppb 10.33 114.23
a units for Quality Controls measured in parts per billion.
Table 4. fu% and plasma free drug concentration of pazopanib at different albumin levels in actual patient plasma samples.
Albumin levels (g/L)
(n ¼ no. of patients)
fu%b (Median  Interquartile range) Plasma free drug concentrationc (ng/mL)
(Median  Interquartile range)
Normal (n ¼ 8) 0.0129  0.0061 4.88  2.71
Low (<40 g/L)
(n ¼ 7)
0.0227  0.0122 6.49  3.65
Very Low (<30 g/L)
(n ¼ 2)
0.0173  0.0060 3.44  1.32
b p-value for Kruskal-Wallis test ¼ 0.43. There were no statistically significant differences between normal, low and very low albumin levels.
c p-value for Kruskal-Wallis test ¼ 0.37. There were no statistically significant differences between normal, low and very low albumin levels.
Y.L. Toh et al. Heliyon 6 (2020) e038134. Conclusion
In summary, we had developed an HPLC-MS/MS coupled with
equilibrium dialysis method for the quantitative determination of plasma
drug concentration of pazopanib and validated the method in accordance
with FDA's guidelines. Applying this assay on actual patient samples,
preliminary data suggested that albumin levels had an influence on
plasma free drug concentration of pazopanib, with higher free pazopanib
concentration and fu% being observed in samples with lower albumin
levels. Future clinical studies may consider analyzing plasma free drug
concentration of pazopanib as an indicator of drug exposure.
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